ECSP088962A - Nuevos herbicidas - Google Patents
Nuevos herbicidasInfo
- Publication number
- ECSP088962A ECSP088962A EC2008008962A ECSP088962A ECSP088962A EC SP088962 A ECSP088962 A EC SP088962A EC 2008008962 A EC2008008962 A EC 2008008962A EC SP088962 A ECSP088962 A EC SP088962A EC SP088962 A ECSP088962 A EC SP088962A
- Authority
- EC
- Ecuador
- Prior art keywords
- new herbicides
- provides
- histidine
- present
- lyophilized formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
En una modalidad, la presente invención proporciona una formulación liofilizada que comprende un anticuerpo anti-EGFR, de preferencia cetuximab; ácido lactobiónico; y una solución reguladora, de preferencia histidina. En una modalidad preferida, la presente invención proporciona una formulación liofilizada estable que comprende aproximadamente 50 mg/mL a aproximadamente 140 mg/mL de ERBITUX, aproximadamente ácido lactobiónico 0.125%, aproximadamente solución reguladora de histidina 25 mM a un pH de aproximadamente 6.0, aproximadamente Tween 80 0.005%, y aproximadamente glicina 1.875%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81395806P | 2006-06-14 | 2006-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088962A true ECSP088962A (es) | 2009-01-30 |
Family
ID=38832820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008962A ECSP088962A (es) | 2006-06-14 | 2008-12-11 | Nuevos herbicidas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100158925A1 (es) |
| EP (1) | EP2029163A4 (es) |
| JP (1) | JP2009540015A (es) |
| KR (1) | KR20090021298A (es) |
| CN (1) | CN101466404A (es) |
| AU (1) | AU2007260769A1 (es) |
| BR (1) | BRPI0713421A2 (es) |
| CA (1) | CA2654794A1 (es) |
| CR (1) | CR10493A (es) |
| EA (1) | EA200870538A1 (es) |
| EC (1) | ECSP088962A (es) |
| IL (1) | IL195794A0 (es) |
| MA (1) | MA30515B1 (es) |
| MX (1) | MX2008015852A (es) |
| NO (1) | NO20085131L (es) |
| TN (1) | TNSN08511A1 (es) |
| WO (1) | WO2007147001A2 (es) |
| ZA (1) | ZA200810456B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666492C (en) | 2006-10-20 | 2012-07-17 | Douglas Rehder | Stable polypeptide formulations |
| ES2759075T3 (es) | 2008-03-14 | 2020-05-07 | Biocon Ltd | Un anticuerpo monoclonal y un método del mismo |
| CN101716343A (zh) * | 2008-10-09 | 2010-06-02 | 哈药集团生物工程有限公司 | 一种单克隆抗体的冻干制剂 |
| FR2944448B1 (fr) * | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| PT3721904T (pt) * | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
| FR2958646B1 (fr) | 2010-04-07 | 2012-05-18 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe. |
| AU2010338305A1 (en) * | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| CN107496917B (zh) | 2010-02-26 | 2021-06-11 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| SG183443A1 (en) | 2010-03-01 | 2012-09-27 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| MX2012013586A (es) | 2010-05-28 | 2013-01-24 | Novo Nordisk As | Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante. |
| CA2803998A1 (en) * | 2010-07-02 | 2012-01-05 | Medimmune, Llc | Antibody formulations |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| PT3024485T (pt) | 2013-07-23 | 2021-01-25 | Biocon Ltd | Utilização de um parceiro de ligação de cd6 e método baseado no mesmo |
| DK3406633T3 (da) * | 2013-07-25 | 2022-03-28 | Cytomx Therapeutics Inc | Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf |
| CN104341505A (zh) * | 2013-07-29 | 2015-02-11 | 西藏海思科药业集团股份有限公司 | 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体 |
| SG11201601770YA (en) * | 2013-09-12 | 2016-04-28 | Halozyme Inc | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| TW201618774A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
| KR20170068409A (ko) | 2014-09-16 | 2017-06-19 | 이즈 참 리미티드 | 항-egfr 항체 및 그의 용도 |
| CN112656939B (zh) * | 2014-09-22 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 一种针对血管内皮生长因子的人源化抗体的药物组合物 |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| KR102548827B1 (ko) * | 2014-12-22 | 2023-06-30 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| WO2017077507A1 (en) | 2015-11-06 | 2017-05-11 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
| EP3529274B1 (en) | 2016-10-21 | 2024-04-17 | Biocon Limited | A monoclonal antibody and a method of use for the treatment of lupus |
| JP7042220B2 (ja) * | 2016-12-28 | 2022-03-25 | Ｊｃｒファーマ株式会社 | 凍結乾燥製剤 |
| US11639391B2 (en) * | 2017-04-18 | 2023-05-02 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
| AU2018347607B2 (en) | 2017-10-14 | 2025-08-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| SG11202011538RA (en) * | 2018-06-01 | 2020-12-30 | Rakuten Medical Inc | Phthalocyanine dye conjugate compositions |
| CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
| TW202521583A (zh) | 2019-01-31 | 2025-06-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| MA55760A (fr) | 2019-04-24 | 2022-03-02 | Regeneron Pharma | Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde |
| JP2022534794A (ja) | 2019-06-04 | 2022-08-03 | サノフィ・バイオテクノロジー | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 |
| KR20220052898A (ko) * | 2019-06-06 | 2022-04-28 | 재눅스 테라퓨틱스 인크. | 종양 활성화 t 세포 인게이저와 관련된 조성물 및 방법 |
| CU20190104A7 (es) * | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
| JP7681681B2 (ja) | 2020-08-11 | 2025-05-22 | ジャナックス セラピューティクス，インク． | 切断可能リンカー組成物および方法 |
| US11555078B2 (en) | 2020-12-09 | 2023-01-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens |
| US20240383968A1 (en) * | 2020-12-11 | 2024-11-21 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application |
| MX2024003989A (es) * | 2021-10-03 | 2024-04-26 | Systimmune Inc | Metodos de tratamiento del cancer y composiciones farmaceuticas de los mismos. |
| JPWO2024058201A1 (es) * | 2022-09-16 | 2024-03-21 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62158160A (ja) * | 1985-12-27 | 1987-07-14 | 堺化学工業株式会社 | 成形触媒及び接触反応方法 |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6695940B2 (en) * | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| PT1735348E (pt) * | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| BRPI0707796A2 (pt) * | 2006-02-15 | 2011-05-10 | Imclone Systems Inc | formulaÇço, e, mÉtodo de tratamento |
-
2007
- 2007-06-13 EP EP07798508A patent/EP2029163A4/en not_active Withdrawn
- 2007-06-13 CA CA002654794A patent/CA2654794A1/en not_active Abandoned
- 2007-06-13 KR KR1020087032258A patent/KR20090021298A/ko not_active Withdrawn
- 2007-06-13 BR BRPI0713421-5A patent/BRPI0713421A2/pt not_active IP Right Cessation
- 2007-06-13 EA EA200870538A patent/EA200870538A1/ru unknown
- 2007-06-13 AU AU2007260769A patent/AU2007260769A1/en not_active Abandoned
- 2007-06-13 JP JP2009515628A patent/JP2009540015A/ja not_active Withdrawn
- 2007-06-13 CN CNA2007800221784A patent/CN101466404A/zh active Pending
- 2007-06-13 WO PCT/US2007/071119 patent/WO2007147001A2/en not_active Ceased
- 2007-06-13 MX MX2008015852A patent/MX2008015852A/es unknown
- 2007-06-13 US US12/308,451 patent/US20100158925A1/en not_active Abandoned
-
2008
- 2008-12-08 IL IL195794A patent/IL195794A0/en unknown
- 2008-12-09 NO NO20085131A patent/NO20085131L/no not_active Application Discontinuation
- 2008-12-10 ZA ZA200810456A patent/ZA200810456B/xx unknown
- 2008-12-11 EC EC2008008962A patent/ECSP088962A/es unknown
- 2008-12-11 TN TNP2008000511A patent/TNSN08511A1/en unknown
- 2008-12-11 CR CR10493A patent/CR10493A/es not_active Application Discontinuation
- 2008-12-12 MA MA31475A patent/MA30515B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200870538A1 (ru) | 2009-04-28 |
| WO2007147001A2 (en) | 2007-12-21 |
| CN101466404A (zh) | 2009-06-24 |
| CA2654794A1 (en) | 2007-12-21 |
| TNSN08511A1 (en) | 2010-04-14 |
| BRPI0713421A2 (pt) | 2012-03-13 |
| ZA200810456B (en) | 2009-12-30 |
| WO2007147001A3 (en) | 2008-07-10 |
| KR20090021298A (ko) | 2009-03-02 |
| AU2007260769A1 (en) | 2007-12-21 |
| MA30515B1 (fr) | 2009-06-01 |
| JP2009540015A (ja) | 2009-11-19 |
| EP2029163A4 (en) | 2010-08-11 |
| NO20085131L (no) | 2009-03-13 |
| IL195794A0 (en) | 2011-08-01 |
| MX2008015852A (es) | 2009-02-23 |
| EP2029163A2 (en) | 2009-03-04 |
| US20100158925A1 (en) | 2010-06-24 |
| CR10493A (es) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088962A (es) | Nuevos herbicidas | |
| ES2569409T3 (es) | Composiciones de anticuerpo anti-CTLA-4 | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| TW200616661A (en) | HER2 antibody composition | |
| CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CL2012001966A1 (es) | Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis. | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
| ATE517922T1 (de) | Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation | |
| BRPI0514340A (pt) | formulações de estabilização | |
| MA33023B1 (fr) | Formulation d'anticorps | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| CR20190400A (es) | Formulaciones de anticuerpo monoclonal anti-vrs | |
| CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
| WO2007014391A3 (en) | Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| RU2009148286A (ru) | Жидкая фармацевтическая композиция ботулинического токсина | |
| MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| ES2531385T3 (es) | Formulación que comprende un anticuerpo contra la selectina P | |
| EA200901365A1 (ru) | Стабилизированная фармацевтическая композиция, содержащая прегабалин | |
| CL2012002948A1 (es) | Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado. |